Shree Ganesh Remedies Limited reported a significant contraction in both top-line and bottom-line figures for the first quarter of FY26. The Ankleshwar-based specialty chemicals manufacturer posted a consolidated net profit after tax of ₹1.12 crore for the quarter ended June 30, 2026, down from ₹3.45 crore in the same period last year.

Revenue from operations declined by 41.8% year-on-year to ₹14.36 crore, compared to ₹24.67 crore in Q1FY25. This sequential drop follows a strong fourth quarter of FY25, where revenue stood at ₹33.20 crore. The company’s earnings per share (EPS) for the quarter were ₹0.87, a sharp decrease from ₹2.68 in Q1FY25.

Financial Performance

The decline in revenue was accompanied by a compression in operating margins. Standalone EBITDA for the quarter was ₹4.29 crore, representing an EBITDA margin of 28.05%. This is lower than the 31.42% margin recorded in Q1FY25 and the 36.23% margin seen in the preceding quarter (Q4FY25).

For the full fiscal year FY25, the company had reported total income of ₹109.29 crore and a net profit after tax of ₹17.76 crore.

What the Numbers Show

The divergence between the sequential and year-on-year performance highlights the volatility in the company’s recent operational cycle. While the current quarter shows a significant YoY decline, it also represents a steep drop from the peak performance recorded in Q4FY25, where revenue was more than double the current quarter’s figure. The compression in EBITDA margins suggests that cost structures did not adjust proportionally to the revenue decline, or that product mix shifted toward lower-margin offerings during the period.

Board Approval

The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors in a meeting held on August 12, 2026. The results have been filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shree Ganesh Remedies Limited reported a significant contraction in earnings for the first quarter of FY27, driven by a steep decline in operating revenue and challenging demand conditions in Europe. The company’s net profit after tax fell 68% year-on-year to ₹1.12 crore for the quarter ended June 30, 2026, compared to ₹3.45 crore in the corresponding period of the previous year.

Revenue from operations declined 42% to ₹14.36 crore, down from ₹24.67 crore in Q1FY26. EBITDA (excluding other income and exceptional items) contracted 54% to ₹3.35 crore, with EBITDA margins compressing by 624 basis points to 23.3%. The sharp decline was attributed to subdued European demand, with customers deferring orders amid geopolitical uncertainty and raw material volatility.

Financial Performance Overview

The consolidated financial results mirrored the standalone figures. Total income for the quarter was ₹15.30 crore, while total expenses stood at ₹13.77 crore. Other income increased 42% to ₹93.92 lakh, providing a partial offset to the top-line weakness.

Revenue Breakdown

Revenue from pharmaceutical intermediates accounted for ₹11.49 crore in Q1FY27, while speciality chemicals contributed ₹2.88 crore. Exports constituted ₹8.64 crore of the total revenue, with domestic sales at ₹5.72 crore.

Expense management saw cost of materials consumed decrease to ₹8.40 crore from ₹8.74 crore in Q1FY26. Employee benefit expenses rose modestly to ₹2.93 crore. Finance costs declined significantly to ₹0.32 crore from ₹0.94 crore. A notable variance appeared in inventory changes, which showed a credit of ₹6.31 crore in Q1FY27, compared to a negligible debit of ₹1.27 lakh in Q1FY26, reflecting a drawdown in stock levels.

Strategic Developments and Business Model Shift

Mr. Gunjan Kothia, Promoter, stated that the marketing and manufacturing agreement with one of the company’s EU distributors reached automatic termination due to non-performance. This development allows Shree Ganesh Remedies to engage directly with customers, though management expects the transition to take a couple of quarters before volumes are meaningfully restored.

On the Contract Research, Development and Manufacturing Services (CRAMS) front, engagements in South-East Asia are progressing as expected, with projects anticipated to begin contributing to revenues from H2FY27. The company also confirmed that Block 7 remains on course for commissioning.

Given the persistent geopolitical headwinds and softer first half, management moderated its earlier guidance for FY27, shifting from "non-linear growth" to expecting meaningful improvement only in the second half of the financial year.

The company released an investor presentation alongside the results, highlighting a strategic pivot in its business model. Historically focused on intermediates for off-patent drugs (contributing >90% of revenue previously), the company is now shifting towards patented molecules and customer-specific innovative molecules. This segment, which entered operations in 2010, is expected to contribute over 60% of revenue in coming years. Project sizes in this vertical have evolved from 20-50 tonnes/year to 80-100 tonnes/year, with current inquiries exceeding 500 tonnes per year.

Infrastructure and Expansion

The investor deck detailed significant infrastructure investments aimed at supporting this transition:

• Dahej Site: The company acquired a 40,554 sq m land parcel at Dahej in 2022 for ₹11 crores. Construction of common infrastructure and utilities has begun. This site is intended to host large-scale custom product requirements for major corporates, featuring capital-intensive plants with high automation.
• R&D Capabilities: The company operates a DSIR-recognised R&D lab with a team of 40 members. It is exploring foreign R&D setups and adding new R&D blocks for pilot trials.
• Pilot Plant Expansion: A new pilot plant facility is being commissioned to bridge the gap between research and commercial production. The existing infrastructure includes reactors with a total capacity of 6,900 Ltr, ranging from 2 Ltr to 1,000 Ltr.

What the Numbers Show

The divergence between the 42% revenue decline and the 54% EBITDA contraction highlights significant margin compression during the quarter. While operating expenses fell 37%, they did not decline proportionately to revenue, indicating fixed cost rigidity. The substantial inventory credit of ₹6.31 crore reduced the cost of goods sold impact but suggests lower production or sales throughput compared to the prior year. The termination of the EU distributor agreement, while strategically aimed at direct customer engagement, introduces near-term execution risk before direct sales channels can stabilize volumes.

Corporate Actions

During its meeting on August 12, 2026, the Board of Directors approved several administrative appointments:

• Cost Auditor: M/s. M. I. Prajapati & Associates LLP was appointed as Cost Auditors for the financial year 2026-2027, effective from August 12, 2026.
• Scrutinizer: Mr. Vishal Thawani of M/s. VTSN and Associates LLP was appointed as Scrutinizer for the e-voting process at the upcoming 31st Annual General Meeting.
• AGM Notice: The Board approved the Notice for the 31st Annual General Meeting along with the Directors’ Report and its annexures for the year ended March 31, 2026.

The unaudited financial results were reviewed by Chaudhary Shah & Associates LLP, the independent auditors, pursuant to Regulation 33 of the SEBI Listing Regulations. The company’s wholly owned subsidiary, SGRL USA Inc., reported nil revenue and nil net profit for the quarter.